For a patient with localized high risk prostate cancer with high risk Decipher score receiving ADT and abiraterone, is there any value of continuing ADT and abiraterone beyond two years?
Answer from: Medical Oncologist at Academic Institution
Since the trial (STAMPEDE) stopped abi at 2 years, that is the longest duration that I use.In the mHSPC setting, we are seeing many patients stay on their first-line treatment for many years (often longer than 2 years). This has made me more cognizant of the long-term effects of abi/prednisone (acce...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I assume you are treating per STAMPEDE platform i.e., N+ or (recently) high risk N0. The trial didn't go past 2 years abi. Toxicity can be substantial and with PSMA PET, I have stopped at 2 years or sooner and conducted vigilant surveillance.